Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 15/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.62 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369696 | 0.95 | FKBP1A (0.66) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5364216 | 0.88 | FKBP1A (0.60) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5365881 | 0.87 | FKBP1A (0.59) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5375908 | 0.86 | FKBP1A (0.58) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5368168 | 0.85 | FKBP1A (0.64) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5367483 | 0.84 | FKBP1A (0.56) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5364249 | 0.83 | FKBP1A (0.55) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5364042 | 0.83 | FKBP1A (0.62) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5364089 | 0.82 | FKBP1A (0.56) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5373037 | 0.78 | FKBP1A (0.53) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417189-B1 | DRUGS WITH PYRAZOLE KETONE DERIVATIVES | GPI NIL HOLDINGS, INC. | 2002-07-09 | — | — | US | claimed |
| US-20020028814-A1 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. | 2002-03-07 | — | — | US | claimed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-6417189-B1 | DRUGS WITH PYRAZOLE KETONE DERIVATIVES | GPI NIL HOLDINGS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020028814-A1 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028814-A1 | Aza compounds, pharmaceutical compositions and methods of use | GRIN3A, CHRNA5, GRIN3B | FKBP1A 1238/4885MTOR 1723/4885FKBP4 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.